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Fibrotic diseases. A therapeutic challenge 
 
There are numerous human diseases including systemic sclerosis; pulmonary, liver, and kidney 
fibrosis; and the newly recognized nephrogenic systemic fibrosis, which are characterized by 
abnormal and exaggerated deposition of collagen in the affected organs (reviewed in refs. 
1-6). Tissue fibrosis causes disruption of normal organ architecture, and ultimately leads to 
their dysfunction and failure. The extent and rate of progression of the fibrotic process largely 
determine the course, response to therapy, and prognosis of these diseases. Although their 
etiology and pathogenesis are diverse and have not been completely elucidated despite 
intensive investigations, it is apparent that a common feature is the accumulation of abundant 
fibrous tissue and the presence of large numbers of fibroblasts displaying an activated 
phenotype. This phenotype is characterized by a notable elevation in the expression of the 
genes encoding type l and type lll collagens and fibronectin, the initiation of expression of α- 
smooth muscle actin, and the reduction in expression of genes encoding extracellular matrix- 
degradative enzymes. Regardless of the etiologic event, the resulting alterations in the 
biosynthetic activity of extracellular matrix producing cells are crucial in the pathogenesis of 
fibrotic diseases. Indeed, it is the persistent activation of the genes encoding various collagens 
in these cells which distinguishes controlled repair, such as that occurring during normal wound 
healing, from the uncontrolled fibrosis which is the hallmark of the fibrotic diseases. However, 
despite numerous recent advances in the molecular biology of the events responsible for the 
regulation of genes encoding collagens and other extracellular matrix proteins, there is limited 
knowledge regarding the intimate mechanisms responsible for the pathologic increase in their 
expression in fibrotic diseases. 
 
The wide spectrum of organs affected by the fibrotic diseases and the large number of 
individuals suffering their devastating effects pose one of the most serious health problems in 
current medicine and represent an enormous burden on health services and resources causing 
severe economic consequences. Despite the high frequency and the diversity of organs affected 
by the fibrotic diseases, there is currently no effective treatment. The recent elucidation of 
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crucial regulatory pathways involved in the fibrotic response has provided a sound basis for 
the development of novel and effective means of therapy. In particular, the identification of 
various important intracellular transduction pathways involved in the transcriptional activation 
of the genes encoding collagens and other proteins responsible for the fibrotic process has been 
of substantial importance. The delineation of the critical role of transforming growth factor-β 
(TGF-β) in the development of exaggerated tissue fibrosis, and the identification of the specific 
cellular receptors, kinases and intracellular mediators which participate in the cellular response 
to TGF-β in the earliest stages of tissue fibrosis, have been the most significant. Unfortunately, 
the current lack of approved drugs capable of modifying these important mechanisms indicates 
that the recently acquired knowledge regarding the pathogenesis of the fibrotic process has not 
been translated into effective therapies in this important area of human health. 
 
Regulation of TGF-β function and signaling 
 
Since the discovery of the potent profibrotic and immunomodulatory activities of TGF-β, this 
growth factor has been recognized as one of the most important molecules in the pathogenesis 
of systemic sclerosis and other fibroproliferative diseases, and a plethora of publications have 
described studies focused on this subject (reviewed in 7). Three functionally and structurally 
similar isoforms of TGF-β exist in humans and they play important roles in embryonic 
development, immune responses, and regulation of tissue repair following injury. One of the 
most important effects of TGF-β is the stimulation of extracellular matrix synthesis as 
evidenced by a remarkable increase in the production of numerous molecules including 
collagens type I, III, V, and VI, as well as, of other relevant proteins such as fibronectin and 
smooth muscle actin, a molecular marker of activated myofibroblasts. TGF-β also decreases 
the synthesis of collagen-degrading metalloproteinases and stimulates the production of 
protease inhibitors such as tissue inhibitor of metalloproteinases-1. Small amounts of TGF-β 
appear to sensitize fibroblasts to its own effects and maintain them in a persistently activated 
state involving an autocrine mechanism that causes further production of TGF-β. Bioactive 
TGF-β in a dimeric form binds to a constitutively active serine/threonine transmembrane kinase 
known as the TGF-βII receptor (TβRII). The signaling events that follow are extremely 
complex and the number of intracellular molecules and pathways involved in the process 
continues to expand (reviewed in 8-10). The classic pathway of TGF-β signal transduction into 
the cell nucleus involves the ligand-bound TβRII which recruits the TGF-βI receptor (TβRI) 
and then transphosphorylates it on three to five serine and threonine residues in a short (30 
amino acid) regulatory sequence known as the GS region as shown in Figure 1. Signaling from 
the phosphorylated TβRI receptor to the nucleus then occurs through the Smad family of 
proteins. Smad2 or Smad3, two of the five receptor activated Smads (RSmads), bind to the 
activated TGF-β receptor complex and become phosphorylated by the activated TβRI at two 
serine residues near their C-end. Phosphorylation allows these proteins to form a complex with 
the co-Smad, Smad4, which is a cytoplasmic protein involved in the translocation of the Smad 
complex across the nuclear membrane into the nucleus. Once in the nucleus, Smad3/Smad4 
complexes act as transcription factors, binding with the help of intranuclear proteins that act 
as transcriptional partners to specific DNA binding sites in the promoter regions of target genes 
and activating their expression. In contrast, Smad2 complexes do not appear to directly bind 
to DNA promoter sites but instead exert their effect through other unidentified transcription 
factors or co-activator proteins. 
 
Numerous recent studies have provided additional details regarding the complex pathways of 
TGF-β modulation of expression of extracellular matrix genes and many participating proteins 
such as FKBP12, SARA, smurfs, co-activators and co-repressors, caveolin1, and others, have 
been identified. Furthermore, it has become apparent that important TGF-β effects may be 
mediated by protein cascades independent of Smad2/Smad3 signaling and that these pathways 
may become activated in a cell-specific and context-dependent manner. For example, it has 
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been shown that there are seven different TβRI molecular species, known as activin receptor- 
like kinases or Alks, encoded in the human genome which exert different and often opposing 
effects or are only functional in specific cell types. The typical TGF-β signaling cascade 
involving the RSmads, Smad2 and Smad3, is initiated by the Alk-5 TβRI, whereas another 
TβRI, Alk-1, initiates activation of the cascade involving RSmads 1, 5, or 8. Although it was 
initially believed that the Alk-1/Smad1, 5, or 8 cascade was activated only by the binding of a 
member of the family of bone morphogenetic proteins (BMPs) or that it was only active in 
endothelial cells, it has now been established that TGF-β can also signal through this pathway 
in fibroblasts (11). To further add to the complexity of the TGF-β activation and signaling 
cascades, it has been recognized that there are numerous other non-Smad mediated events 
involved in TGF-β functions and effects (12). Of particular relevance to the present discussion 
is the recent finding that one of these non-Smad pathways results in the activation of the non- 
receptor tyrosine kinase, c-Abl (13), apparently through the sequential action of 
phosphatidylinositol 3-kinase (PI3K) and p-21 activated kinase 2 (PAK2) as shown in Figure 
1. 
 
TGF-β as a target of antifibrotic therapies 
 
The crucial role that TGF-β plays in the initiation and progression of tissue fibrosis and the 
recognition of its participation in the pathogenesis of numerous fibrotic diseases has focused 
substantial attention on this growth factor as a target for the development of anti-fibrotic 
therapies. Indeed, several strategies have been developed to block TGF-β effects, including 
soluble TβRll fragments, decorin, tranilast, TGF-β-neutralizing antibodies, threonine kinase 
inhibitors, RNA expression inhibitors such as anti-sense expression vectors, small inhibitory 
RNA (siRNA) or blocking oligoncleotides, and reduction of TGF-β gene transcription with 
pirfenidone. However, despite the intensive investigation in vitro as well as in vivo in various 
animal models of fibrosis and in some studies in human subjects, these approaches have either 
not been effective or are still in the experimental/clinical trial stage and, therefore, are not 
presently available for clinical use. 
 
Tyrosine kinase inhibitors 
 
Protein kinase inhibitors are a relatively new class of therapeutic agents that are capable of 
potent modulation of several cellular phenotypes in oncologic and in chronic inflammatory 
diseases. Of particular interest in the present context are results of numerous recent studies 
demonstrating that the non-receptor kinase c-Abl participates in some of the TGF-β 
downstream signaling responsible for the development of a profibrotic phenotype response in 
a variety of cell types. The initial observations leading to this important discovery appeared in 
the hematologic literature with three reports describing simultaneously a remarkable reduction 
of bone marrow fibrosis in patients receiving treatment for chronic myelogenous leukemia with 
the c-Abl inhibitor, imatinib mesylate (14-16)`. Several subsequent studies confirmed the 
marked improvement in myelofibrosis following imatinib administration. Imatinib is the 
prototypical drug of the novel class of non-receptor kinase inhibitors. It is a 
phenylaminopyrimidine-derived small molecule capable of exerting a potent inhibition of 
several tyrosine kinases including BCRc-Abl, c-Abl, C-kit, and the platelet derived growth 
factor receptor (PDGFR) at micromolar concentrations. Although the initial kinetic analysis 
of the mechanisms involved in the potent inhibition of BCRc-Abl kinase by imatinib indicated 
that this drug binds to the ATP-binding pocket of c-Abl and efficiently blocks its tyrosine 
kinase activity, further studies have shown that the binding occurs near the ATP-binding pocket 
resulting in a profound conformational change of the kinase active site domain stabilizing it in 
an inactive conformation. Following the initial studies describing inhibition of bone marrow 
fibrosis by imatinib, several investigators examined the effects of the drug on in vitro and in 
vivo models of fibrotic diseases. A landmark study by Daniels et al. (17) examined the effects 
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of imatinib on TGF-β signaling in fibroblasts and on the development and progression of 
bleomycin-mediated lung fibrosis in mice. The results showed that TGF-β stimulated c-Abl 
kinase and that imatinib abolished the fibrogenic response of fibroblasts to exogenous TGF- 
β in a Smad2/Smad3 independent manner. Furthermore, they showed that in vivo 
administration of imatinib in mice abrogated the biochemical and morphological changes of 
bleomycin-induced lung fibrosis. Several subsequent reports explored in further detail the 
mechanisms of TGF-β signaling inhibition by imatinib and confirmed the potent effects of the 
drug in abrogating experimentally induced fibrotic processes such as liver, renal, and 
myocardial fibrosis (18-20). A more recent in vitro and in vivo study examined the effects of 
imatinib on collagen gene expression by dermal fibroblasts cultured from patients with 
systemic sclerosis and demonstrated that c-Abl appeared to have a novel and important function 
in TGF-β-induced fibrotic responses. Furthermore, this study showed that c-Abl inhibition with 
imatinib abrogated the development of cutaneous fibrosis induced by bleomycin in mice, a 
process which mimics the skin fibrosis of systemic sclerosis (21). Similar observations were 
recently published by Distler et al. (22), confirming the potent inhibitory effect of imatinib on 
the development of scleroderma-like cutaneous alterations in mice receiving dermal injections 
of bleomycin. Although numerous studies have conclusively demonstrated the participation of 
c-Abl in the regulation of genes associated with the fibrotic process, the molecular events 
occurring downstream from c-Abl and the intimate mechanisms of its participation in the 
regulation of gene expression remain elusive. 
 
The light at the end of the tunnel for patients with systemic sclerosis and 
other fibrotic diseases? 
There are four interesting articles published in this issue of Arthritis and Rheumatism which 
corroborate the potential importance of imatinib in the therapy of a spectrum of fibrotic 
diseases. In the paper by Pannu et al., studies with skin biopsies from 8 normal individuals and 
from 8 patients with systemic sclerosis and with cultured fibroblasts from these biopsies 
demonstrated activation of a novel pathway of TGF-β signaling in fibroblasts involving Alk-1 
and Smad1 leading to the transcriptional activation of the connective tissue growth factor gene 
(CTGF/CCN-2). Furthermore, Pannu et al. failed to find any differences in the amounts of 
phosphorylated Smad3 between normal fibroblasts and fibroblasts cultured from skin of 
systemic sclerosis patients. These results are in contrast to those described by other 
investigators who postulated that the excessive tissue fibrosis in systemic sclerosis was 
mediated by activation of the Alk-5/Smad3 pathway. Of substantial relevance to this discussion 
was the observation that this pathway of TGF-β signaling and the consequent activation of 
CTGF/CCN-2 were abolished by addition of imatinib to the cultured fibroblasts. The important 
role of c-Abl in the activation of the Alk-1/Smad1 pathway and in the phosphorylation of 
Smad1 was further confirmed employing a specific c-Abl siRNA which completely abolished 
Smad1 phosphorylation and, remarkably, normalized the excessive collagen production in 
systemic sclerosis fibroblasts. Although these findings indicate that Smad1 phosphorylation is 
a downstream effect mediated by c-Abl, the mechanisms involved are not known. Since 
phosphorylation and activation of all RSmads is accomplished through specific kinase domains 
of Alk receptors, the participation of c-Abl in the phosphorylation of Smad1 is puzzling and 
requires further investigation. The second paper, by van Daele et al., describes studies 
performed with lung fibroblasts obtained from bronchial biopsy specimens from a patient with 
systemic sclerosis and pulmonary fibrosis in whom the lung involvement progressed despite 
treatment with twice monthly intravenous cyclophosphamide and low dose corticosteroids. 
Imatinib prevented proliferation of cultured fibroblasts induced by PDGF as well as TGF-β 
stimulation of collagen type l gene transcription in vitro. Significantly, treatment of this patient 
with imatinib resulted in improvement in skin tightness with a reduction of Rodnan skin score 
(RSS) from 18 before treatment to 12 three months after initiation of imatinib and stabilization 
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of pulmonary function and computerized tomography (CT) scanning findings. A third study 
by Distler et al. showed that 20 week treatment with imatinib caused remarkable improvement 
in the pulmonary function and CT findings of a patient with mixed connective tissue disease 
associated with rapidly progressive pulmonary fibrosis. The fourth report by Kay and High 
found that treatment with imatinib decreased fibrosis and resulted in relatively rapid 
improvement of skin changes and knee joint contractures in two patients with nephrogenic 
systemic fibrosis (NSF). NSF is a recently recognized fibrotic disease characterized by severe 
cutaneous and visceral fibrosis occurring almost exclusively in patients with renal insufficiency 
following administration of gadolinium containing contrast agents for magnetic resonance 
imaging. Severe and progressive joint contractures causing disabilities occur frequently in 
these patients. The cases reported by Kay and High showed substantial clinical improvement 
as well as histopathological evidence of reduction of collagen biosynthesis following treatment 
with imatinib. These four papers provide valuable information regarding the novel role of c- 
Abl in tissue fibrosis and, more importantly, bring closer the promise of “light at the end of 
the tunnel” for patients affected by these diseases as stated in a recent editorial by Wolheim 
(23). 
 
Speculations and caveats 
 
Several promising therapeutic agents have previously been tested in a variety of fibrotic states, 
but in most instances with disappointing results. There is great interest and expectation about 
the possibility that imatinib, a drug approved for use in chronic myelogenous leukemias and 
gastrointestinal stromal tumors (GIST), may also have a therapeutic effect for fibrotic diseases. 
Currently there is only limited experience with the use of imatinib for treatment of fibrotic 
diseases. Thus, given the disappointing results from clinical trials of several promising 
antifibrotic agents previously studied, it is essential that imatinib and similar drugs be shown 
to be effective in a large cohort of patients in well controlled studies prior to their widespread 
use to treat fibrotic diseases. Imatinib has been used extensively in the treatment of chronic 
myelogenous leukemia and GIST with spectacular results and relatively little toxicity 
considering the outstanding benefits achieved. However, one or more adverse reactions 
including congestive heart failure, edema, muscle cramps, diarrhea, anemia, neutropenia and 
thrombocytopenia occurred in a substantial proportion of the treated patients. It must, therefore, 
be demonstrated that long term use of imatinib is free of substantial side effects in patients with 
severe fibrotic diseases, in particular, regarding its cardiotoxicity given the reduced cardiac 
functional reserve of patients with systemic sclerosis, pulmonary fibrosis, and nephrogenic 
systemic fibrosis. We have reason to be encouraged, but there is only limited knowledge 
concerning the signaling pathways in which the pertinent tyrosine kinases participate in relation 
to stimulation of fibrosis. While it presently appears that many fibrotic reactions, irrespective 
of initiating events, terminate in a final common pathway susceptible to this therapeutic 
intervention, this optimistic view must be substantiated. 
 
Acknowledgments 
 
Supported by NIH Grant AR01916 to S.A.J. The authors thank Susan V. Castro, Ph.D. for her assistance in the 
preparation of the illustration and the manuscript. 
 
Bibliography 
 
1. Varga J, Abraham D. Systemic Sclerosis: A prototypic multi-system fibrotic disorder. J Clin Invest 
2007;117:557–567. [PubMed: 17332883] 
2. Jimenez SA, Derk CT. Following the molecular pathways toward and understanding of the 
pathogenesis of Systemic Sclerosis. Ann Int Med 2004;140:37–50. [PubMed: 14706971] 
3. Gharakee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for 
idiopathic pulmonary fibrosis. Curr Pharm Des 2005;11:3943–3971. [PubMed: 16305523] 
 
Arthritis Rheum. Author manuscript; available in PMC 2009 September 18. 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
Rosenbloom and Jimenez Page 6 
 
4. Tskada S, Parson CJ, Rieppe RA. Mechanisms of liver fibrosis. Clin Chim Acta 2006;364:33–60. 
[PubMed: 16139830] 
5. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213– 
217. [PubMed: 16408108] 
6. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 
cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 
2006;35:238–249. [PubMed: 16461069] 
7. Blobe GC, Schiemann EP, Lodish HF. Role of transforming growth factor β in human disease. N Engl 
J Med 2000;342:1350–1358. [PubMed: 10793168] 
8. Schmierer B, Hill CS. TGFβ-SMAD signal transduction: molecular specificity and functional 
flexibility. Nat Rev Mol Cell Biol 2007;8:970–82. [PubMed: 18000526]Review 
9. Massagué J, Gomis RR. The logic of TGFβ signaling. FEBS Lett 2006;580:2811–20. [PubMed: 
16678165]Review 
10. Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005;19:2783–810. 
[PubMed: 16322555]Review 
11. Rahimi RA, Leof EB. TGF-β signaling: a tale of two responses. J Cell Biochem 2007;102:593–608. 
[PubMed: 17729308]Review 
12. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signaling. 
Nature 2003;425:577–584. [PubMed: 14534577] 
13. Wilkes MC, Leof EB. Transforming growth factor beta activation of c-Abl is independent of receptor 
internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. 
J Biol Chem 2006;281:27846–27854. [PubMed: 16867995] 
14. Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Höfler G, Haas OA, Linkesch W. Treatment 
of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked 
regression of bone marrow fibrosis. Blood 2002;99:381–3. [PubMed: 11756197] 
15. Hasserjian RP, Boecklin F, Parker S, Chase A, Dhar S, Zaiac M, Olavarria E, Lampert I, Henry K, 
Apperley JF, Goldman JM. ST1571 (imatinib mesylate) reduces bone marrow cellularity and 
normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 
2002;117:360–7. [PubMed: 11888075] 
16. Hirose Y, Kiyoi H, Iwai M, Yokozawa T, Ito M, Naoe T. Successful treatment with imatinib mesylate 
of a CML patient in megakaryoblastic crisis with severe fibrosis. Int J Hematol 2002;76:349–53. 
[PubMed: 12463599] 
17. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate 
inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin 
Invest 2004;114:1308–16. [PubMed: 15520863] 
18. Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, Kitade M, Masaki 
T, Fukui H. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol 
Gastrointest Liver Physiol 2005;288:G907–13. [PubMed: 15618280] 
19. Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta 
pathway and reduces renal fibrogenesis in vivo. FASEB J 2005;19:1–11. [PubMed: 15629889] 
20. Leipner C, Grün K, Müller A, Buchdunger E, Borsi L, Kosmehl H, Berndt A, Janik T, Uecker A, 
Kiehntopf M, Böhmer FD. Imatinib mesylate attenuates fibrosis in coxsackievirus B3 (CVB3)- 
induced chronic myocarditis. Cardiovasc Res. 2008 Mar 7;Epub ahead of print 
21. Ishida W, Bhattacharyya S, Hinchcliff M, Mori Y, Wu M, Takagawa S, Takehara K, Varga J. Novel 
Role of C-abl Tyrosine Kinase in Profibrotic TGF-Beta Responses: Selective Modulation By the 
Anticancer Drug Imatinib Methylate (gleevec). Arthritis Rheum 2006;54(Suppl):S776.Abstract 1975 
22. Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett 
G, Gay S, Distler O. Imatinib mesylate reduces production of extracellular matrix and prevents 
development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311–22. [PubMed: 
17195235] 
23. Wollheim FA. Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel? 
Arthritis Rheum 2007;56:9–12. [PubMed: 17195185] 
 
 
 
 
Arthritis Rheum. Author manuscript; available in PMC 2009 September 18. 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
Rosenbloom and Jimenez Page 7 
 
 
 
Figure 1. TGF-β signaling pathways critical for the fibrotic response 
Illustrated are two canonical Smad pathways originating from two representative tetrameric 
receptors. After TGF-β binding, the TGFβRII receptor recruits a type1 receptor (TGFβRI) and 
activates it by phosphorylation. Alk-5 then specifically phosphorylates receptor-regulated 
Smad 2 and Smad3 whereas Alk-1 phosphorylates Smad1 (Smad5 and Smad8, also activated 
by Alk-1, are not illustrated). The receptor Smads then complex with Co-Smad4 resulting in 
their transport to the nucleus where they cooperate with other factors to regulate transcription 
of critical genes, here represented by CTGF and α2(I) collagen. Also illustrated is a non- 
canonical pathway resulting in the activation of c-Abl. As pictured, imatinib blocks the activity 
of c-Abl, effectively inhibiting the fibrotic response although the events downstream of c-Abl 
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are presently unknown. Imatinib also blocks the phosphorylation of Smad1, but here also the 
pathway is unknown. 
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